IBDX® is the most reliable and cost-effective serological biomarkers panel for the aid in deferential diagnosis of IBD vs. non-IBD and for CD vs. UC, as well as for predicting the probability of Crohn's Disease progression.

As of 2016, the IBDX panel biomarkers: gASCA, ALCA, ACCA, AMCA, Anti-L and Anti-C were analyzed on over 7500 of patient samples in multiple independent clinical studies around the globe, including: Australia, Belgium, Canada, China, Czech Republic, Saudi Arabia, France, Germany, Greece, Hungry, Italy, Israel, Poland and the U.S..
For publications see >>